

Article

Docetaxel-loaded Poly(3HB-co-4HB) Biodegradable Nanoparticles: Impact of Co-polymer Composition

Faisalina Ahmad Fisol¹, Fabio Sonvico^{2*}, Paolo Colombo², Amirul Al-Ashraf Abdullah¹, Habibah A. Wahab^{1,*}, Mohamed Isa Abdul Majid¹

¹ Malaysian Institute of Pharmaceuticals and Nutraceuticals (IPharm), National Institute of Biotechnology Malaysia (NIBM), Ministry of Science, Technology and Innovation (MOSTI), Penang, Malaysia; faisalinafisol@gmail.com (F.A.F.); amirul@usm.my (A.A.A.); bibwahab@gmail.com (H.A.W.); isa_majid@usm.my (M.I.A.M)

² Food and Drug Department, University of Parma, Parma, Italy; fabio.sonvico@unipr.it (F.S.), paolo.colombo@unipr.it (P.C.)

* Correspondence: bibwahab@gmail.com, Tel.: +604-6577888 (Ext.2228) (H.A.W.); fabio.sonvico@unipr.it, Tel. +39-0521906282 (F.S.)

Abstract: Polyhydroxyalkanoate (PHA) co-polymers show relatively higher *in vivo* degradation rate compared to other PHAs thus they received a great deal of attention for a wide range of medical applications. Nanoparticles (NPs) loaded with poorly water soluble anticancer drug docetaxel (DCX) were produced using poly 3-hydroxybutyrate-co-4-hydroxybutyrate, P(3HB-co-4HB), co-polymers biosynthesised from *Cupriavidus sp.* USMAA1020 isolated from Malaysian environment. Three co-polymers with different molar proportions of 4-hydroxybutyrate (4HB) were used: 16% (PHB16), 30% (PHB30) and 70% (PHB70) 4HB-containing P(3HB-co-4HB). Blank and DCX loaded nanoparticles were then characterized for their size and size distribution, surface charge, encapsulation efficiency and drug release. Pre-formulation studies showed that an optimised formulation could be achieved through the emulsification/solvent evaporation method using PHB70 with the addition of 1.0% PVA, as stabilizer and 0.03% VitE-TPGS, as surfactant. DCX-loaded PHB70 nanoparticles (DCX-PHB70) gave the desired particle size distribution in term of average particles sizes around 150 nm and narrow particle size distribution (PDI below 0.100). The encapsulation efficiencies result showed that at 30% w/w drug-to-polymer ratio: DCX- PHB16 NPs were able to encapsulate up to 42% of DCX; DCX-PHB30 NPs encapsulated up to 46% of DCX and DCX-PHB70 NPs encapsulated up to 50% of DCX within the nanoparticles system. Approximately 60% of DCX was released from the DCX-PHB70 NPs within 7 days for 5%, 10% and 20% of drug to polymer ratio while for the 30% and 40% drug to polymer ratios, an almost complete drug release (98%) after 7 days of incubation was observed.

Keywords: Biodegradable polymers, Nanoparticles, Cancer chemotherapy, Controlled release, Drug delivery systems.

1. Introduction

In the last decades, remarkable progresses has been witnessed in the research and development of biocompatible and biodegradable polymers for drug delivery and in particular for their use in micro/nanoparticles manufacturing[1]. Biodegradable polymers such as poly(glycolide) (PGA), poly(lactic acid) (PLA), poly(lactide-co-glycolide) (PLGA), poly(ϵ -caprolactone) (PCL), poly(3-hydroxybutyrate) (PHB), poly(2-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV), gelatine, chitosan (CHI), and alginate (ALG) are among popular polymers being used for this purpose [2–4]. Another polymer which appears interesting for the preparation of biocompatible and biodegradable nanoparticles is poly(3-hydroxybutyrate-co-4-hydroxybutyrate), P(3HB-co-4HB) [5,6].

P(3HB-co-4HB) is a biodegradable polymer from polyhydroxyalkanoates (PHA) group that has properties similar to synthetic thermoplastics. This polymer can be tailored by varying its composition to achieve a range of materials with different mechanical and functional characteristics, from hard crystalline plastics to very elastic rubbers [5,7]. The *in vivo* degradation kinetics of P(3HB-co-4HB) are relatively fast compared to other PHAs, and they can be modulated by varying the 4-hydroxybutyrate fraction (Saito et al., 1996). Generally, P(3HB-co-4HB) is produced by feeding precursor carbon sources such as 4-hydroxybutyric acid, 1,4-butanediol and γ -butyrolactone to diverse wild-type bacteria. In particular, wild-type and recombinant strains of *Cupriavidus necator* and *Delftia acidovorans* are commonly investigated for P(3HB-co-4HB) production using various carbon precursors, in addition to *Escherichia coli* which can be genetically modified to produce this co-polymer from unrelated carbon sources such as glucose [8,9]. P(3HB-co-4HB) has attracted a special interest among PHAs in the biomedical field since the hydrolysis of P(3HB-co-4HB) yields 4HB, a natural human metabolite presents in blood. P(4HB) is metabolized by depolymerases, lipases as well as esterases [10,11]. The utilization of large doses of this polymer in the medical fields has been approved in view of the relatively slow rate conversion of P(4HB) to 4HB and due to the fact that P(4HB) exhibited high tolerance *in vivo*. This polymer is thus considered as an excellent biomaterial as it adheres to the strict regulations by Food and Drug Administration (FDA) [5]. As a consequence, P(3HB-co-4HB) has been proposed a wide variety of biomedical applications such as in tissue engineering [12,13], wound healing[14] and drug delivery field[15,16]. In particular, PHBs applications as drug carriers for anti-cancer compounds have received significant attention [6,17,18] However, proper formulation of the microsphere/microcapsule/nanoparticles of PHB-containing desired drugs remains an aspect of important concern to ensure that the properties of the drug and/or PHB are not affected and that the releasing speed of the drug is close to its target [19]. Encouraged by this, in this study, we reported the utilisation of P(3HB-co-4HB) biosynthesized from *Cupriavidus sp.* USMAA1020, isolated from sludge samples obtained from a local lake in Kulim, Malaysia [20] for the preparation of nanoparticles for delivery of the anti-cancer drug docetaxel.

Docetaxel is a second-generation taxane semi-synthetically derived from a precursor extracted from the needles of the European yew tree, *Taxus baccata*. Docetaxel is approved for the treatment of breast and lung cancer, hormone-refractive prostate cancer and advanced gastric cancer. The antitumor mechanism of action for docetaxel is the hyperstabilisation of microtubules [21]. DCX binds preferentially to tubulin β -subunit in the microtubules and promotes assembly of tubulin into stable microtubules while simultaneously inhibiting their depolymerisation. The formation of stable microtubule bundles disrupts the normal dynamic equilibrium between polymerization and depolymerisation within the microtubule system and leads to cell cycle arrest at the G2/M phase and, ultimately, cell death. Although this antitumor mechanism of action similar to that of paclitaxel, DCX shows a higher affinity for the microtubule binding site and is approximately twice as potent as paclitaxel [22].

Although DCX showed significant antitumor activity against a broad spectrum of human tumours, it has very low water-solubility (6-7 $\mu\text{g}/\text{mL}$), requiring the inclusion of surfactant such as polysorbate 80 or solubilized in ethanol to improve the solubility (Du et al., 2007). Both, polysorbate 80, a low molecular weight surfactant, and ethanol, have been reported to produce side-effects, including acute hypersensitivity reactions as well as pleural or pericardial effusions (Engels et al., 2007). Therefore, the production of docetaxel-loaded nanoparticles is seen as a strategy to overcome traditional formulations side effects and to improve drug efficacy through accumulation of the nanocarrier in the tumor parenchyma as a result of the enhanced permeation retention effect [23].

2. Materials and Methods

2.1. Materials

Polyhydroxyalkanoates with three different co-monomer compositions were synthesized in house using wild-type and transformant strains of *Cupriavidus sp.* USMAA1020 isolated from Lake Kulim (Malaysia) through a two stage cultivation in shake-flasks, as it leads in higher 4HB molar fraction described elsewhere[20] The three co-polymer compositions used in this study were: 16 mol% (PHB16), 30 mol% (PHB30), and 70 mol% (PHB70) of 4HB over 3HB ratio. During the pre-formulation study, the surfactants used for nanoparticle production were polyvinyl alcohol (PVA, Mw10,000 Da, Sigma-Aldrich, Steinheim, Germany), polyoxyethylene-polyoxpropylene poloxamer block co-polymer (Pluronic® F-68, Sigma Aldrich, St. Louis, MO, USA), L- α -phosphatidylcholine from soybean Type II-S (Sigma-Aldrich, Steinheim, Germany) and vitamin E derivative D- α -tocopherol polyethylene glycol 1000 succinate (TPGS, International Laboratory, South San Francisco, CA, USA). The active ingredient, docetaxel (99+%) was obtained from International Laboratory (South San Francisco, CA, USA). Other solvents and chemicals such as dichloromethane, acetonitrile, sodium dihydrogen phosphate anhydrous, hydrochloric acid were of analytical grade.

2.2. Optimisation of P(3HB-co-4HB) Nanoparticles Production Conditions

The co-polymer PHB70, *i.e.* P(3HB-co-70%4HB), was selected for the preliminary screening in terms of type and concentration of tensioactives to be used in nanoparticles preparation. P(3HB-co-4HB) nanoparticles were prepared using an oil-in-water (o/w) emulsion/solvent evaporation method slightly modified from Poletto and co-workers [24]. Briefly, P(3HB-co-4HB) (50.0 mg) was dissolved in 10.0 mL of dichloromethane. The aqueous phase (40.0 mL) contained 1.0 % w/v PVA and different concentrations (0.03 - 0.5 % w/v) of one tensioactive among lecithin, Pluronic F-68 and vitamin E TPGS. The organic solution was emulsified into the aqueous phase using a mechanical disperser for 5.0 min at 17,600 rpm (T25 digital Ultra-turrax®, IKA, Staufen, Germany) and 5.0 min sonication using an ultrasound homogenizer (Labsonic M, Sartorius, Göttingen, Germany; operating frequency 30 Hz, output 100W, 90 % amplitude) *ase*. The organic phase of the resulting emulsion was then evaporated overnight at room temperature under constant magnetic stirring at 400 rpm (RH digital, IKA, Staufen, Germany).

Finally, PHB16, PHB30 and PHB70 nanoparticles were prepared as described above using an aqueous phase (40.0 mL) containing 1.0% w/v PVA and 0.03% w/v TPGS was added drop wise into the organic phase. Docetaxel loaded nanoparticles (DCX-PHB16, DCX-PHB30 and DCX-PHB70) were obtained by dissolving the drug in the organic phase along with the polymer. Nanoparticles with different drug/polymer percentage ratio by weight (5, 10, 20, 30, 40% w/w) were produced in order to evaluate drug loading capacity with all three co-polymers.

All experiments were performed in triplicate.

2.3. P(3HB-co-4HB) Nanoparticles Physicochemical Characterization

The mean particle size, polydispersity index (PDI), and zeta potential were determined by dynamic light scattering using a ZetaSizer Nano-ZS 90 (Malvern Panalytical, Malvern, UK). The determination of nanoparticles sizes and PDI were carried out after dilution (1:100) in deionized water, at 25°C. The measurement parameters used were as follows: material RI 1.59, material absorption 0.01, dispersant RI 1.330 and viscosity 0.8872. A total analysis time of 10 minutes per sample was used.

The obtained suspension was determined for particle size and polydispersity while for zeta potential measurement, the same measurement process as described above were used. However, the operating parameters were: dispersant RI 1.330, viscosity 0.8871 and dielectric constant 78.5, temperature 25°C and number of runs 12. Each measurement was performed in triplicate.

The shape and surface morphology of the produced nanoparticles were investigated by the scanning electron microscopy (SEM) (Leo Supra 50VP Field Emission SEM, Carl-Zeiss SMT, Oberkochen, Germany). SEM required a previous coating of the sample with gold, which was

performed in a gold coated machine (SC515, Polaron Equipment Ltd., Watford, UK). Prior to the viewing. Samples were diluted (1:5) and dried in room temperature overnight before they were fixed on a double-sided sticky tape that was stuck on the standard sample stand.

2.4. Determination of Docetaxel-loaded P(3HB-co-4HB) Nanoparticles Encapsulation Efficiency

The docetaxel was analyzed using a HPLC-UV method adapted from literature[25]. The HPLC system used was an Agilent 1260 Infinity LC System (Agilent Technologies Inc., Santa Clara, CA, USA) equipped with a UV detector set at 230 nm. The mobile phase was a 50:50 mixture of acetonitrile and phosphate buffer (0.02 M, pH 2) eluted with a flow rate of 0.5 mL/min. The analysis was carried out using a reverse-phase C18 column (Gemini, 3x150 mm, 5 μ m, Phenomenex, Singapore) maintained at 30°C. Sample injection volume was 100 μ L. Under these experimental conditions the total run time was 10 min and docetaxel (DCX) retention time was 6.7 min. The calibration curve was linear over the range of 0.05- 20.00 μ g/mL ($r^2 > 0.9999$). Limit of detection (LOD) of the method was calculated to be 29.63 ng/mL while limit of quantification (LOQ) was 89.80 ng/mL.

In order to characterize nanoparticles for encapsulation efficiency, nanoparticles were separated from larger particles and from the dispersant liquid by subsequent centrifugation steps. Initially, 10.0 mL of the nanoparticles suspension were centrifuged for 5.0 min at 5,000 rpm (Sigma 318-K Benchtop centrifuge, Sororius, Göttingen, Germany) to separate eventual agglomerates or precipitated drug from the nanoparticles suspension. The nanoparticles suspension was removed and the pellet obtained was dissolved in 5.0 mL acetonitrile and sonicated for 30.0 min before adding 5.0 mL of phosphate buffer (0.02 M, pH2) to proceed with HPLC quantification. To separate free dissolved docetaxel in the suspension from nanoparticles, 4.9 mL of the nanoparticles suspension was then ultracentrifuged for 1 hour at 52,600 rpm (Optima Max-XP Ultracentrifuge, Beckman Coulter Inc., Calsbad, CA, USA). The recovered supernatant was directly analyzed with HPLC while the obtained pellet was resuspended in 2.0 mL dichloromethane and sonicated for 1 hour with ultrasonic bath (FBI5055, Fisher Scientific, Waltham, MA, USA) to dissolve docetaxel loaded into nanoparticles. The dichloromethane solution was added to 10.0 mL of HPLC mobile phase and the chlorinated solvent was evaporated overnight at room temperature under magnetic stirring at 100 rpm before quantifying by HPLC analysis the encapsulated docetaxel.

For analysis, the samples were solubilized with acetonitrile (1/5, v/v). Then the samples were transferred into auto-sampler vials, capped and placed in HPLC auto-sampler. All samples were filtrated on 0.22 μ m filters prior to the injection in the HPLC apparatus. Then, 100 μ L aliquots were injected onto HPLC column. Each sample were analyzed in triplicate. Drug loading was expressed as the amount of docetaxel (in μ g) per mg nanoparticles.

2.5 In Vitro Drug Release Experiments

In vitro release studies of docetaxel from docetaxel loaded P(3HB-co-4HB) NPs were carried out using a dialysis membrane method reported in literature with some modifications (Song et al., 2008). Briefly, a volume of DCX loaded P(3HB-co-4HB) NPs sufficient to reach a concentration of 500 μ g/mL of total drug was put into a regenerated cellulose dialysis tubes (Spectrum Spectra/Por[®] 6, MW cut-off 12,000-14,000 Da, Fisher Scientific, Waltham, MA, USA) containing 8.0 mL total volume. Then, the dialysis bag was placed in 400.0 mL phosphate buffer solution (PBS, pH 7.4) to maintain sink conditions and stirred in an incubator shaker (Certomat[®] IS, Sartorius, Göttingen, Germany) at 100 rpm and 37°C. At regular time intervals, 1.0 mL of the release medium was removed and replaced with fresh PBS. The docetaxel released was quantified by HPLC. A control experiment to determine the release behavior of the free drug across the dialysis membrane was also performed placing the same amount of docetaxel as it was in DCX-P(3HB-co-4HB) NPs.

3. Results

3.1. Optimisation of P(3HB-co-4HB) Nanoparticles Production Conditions

Three surfactants, *i.e.* lecithin, Pluronic F-68 and TPGS, were chosen with the aim to investigate which type of tensioactive could be work best for the production of P(3HB-co-4HB) nanoparticles by the emulsification/ solvent evaporation method. In this phase the co-polymer PHB70 in combination with low molecular weight PVA as stabilizer in the aqueous phase. Figure 1 shows mean particle size and PDI of the nanoparticles obtained adding increasing concentrations (from 0.03% to 0.5% w/v) of each of the three surfactants in combination with 1.0% PVA.




Figure 1. Particle size (a) and zeta potential (b) of PHB70 nanoparticles produced by emulsion/solvent evaporation method with 1.0 % w/v PVA (Mw 10,000 Da) combined with different concentrations of tensioactives: lecithin (black bars), Pluronic F-68 (white bars) and TPGS (grey bars). Each value represents the mean and standard deviation of three independent replicates (n=3).

In general, the higher the concentration of the tensioactive, the smaller the size of the nanoparticles, however for PHB70 nanoparticles obtained was found to be more or less the same size (below 200 nm) regardless the tensioactive type and concentration (Figure 1a). Lecithin at 0.05% w/v provided the larger particles (195.2 nm) while the presence of TPGS as surfactant led to the smaller group nanoparticles (150.0-172.0 nm) were produced All PHB70 nanoparticles obtained showed with narrow size distribution with PDI in the range between 0.211 and 0.100. In particular, Pluronic F-68 provided the particles with the lower PDI (all values lower than 0.125). Concerning nanoparticles surface charge in the case of Pluronic F-68 and TPGS stabilized nanoparticles, the zeta potential values were negative (from -21.7 to -25.3 mV) and quite reproducible. When lecithin was used, the zeta potential values were still negative but extremely variable ranging from -10.3 mV to -47.4 mV. This variability could explain the fluctuating values evidenced both for size and PDI for lecithin stabilized PHB70 nanoparticles.

Taken into consideration all the data, it was considered that nanoparticles produced using 0.03 % TPGS combined with 1.0 % PVA 10 000 Da provided the best compromise in terms of PHB70 nanoparticles physicochemical characteristics: small particle size (169.6 nm), highly monodispersed (PDI 0.14) and acceptable surface charge value (-23.0 mV).

Thus, considering these results, the manufacturing conditions including 0.03 % TPGS with 1.0 % PVA was chosen to be applied for the screening P(3HB-co-4HB) co-polymers nanoparticle formulations. This choice was corroborated by a three months stability study of unloaded P(3HB-co-4HB) that was conducted to investigate the storage conditions effect on P(3HB-co-4HB) nanoparticles physicochemical properties such as size, PDI and surface charge at 25°C (room temperature), 4°C (refrigerator) and 35°C (see **Supplementary Materials**). All the formulations showed no marked differences in terms of physicochemical properties and no sign of precipitation or agglomeration (Figure S1). In fact, although average particle size slightly increased with respect to the initial values,

all nanoparticles mean particle size was still below 200 nm with low PDI (<0.2). These results indicate that P(3HB-co-4HB) nanoparticles manufactured in the selected conditions were stable and that the nanoparticles could be stored up to 90 days in different temperature condition from 4°C to 35°C without major effects on their physicochemical characteristics.

3.2 Characterization of P(3HB-co-4HB) nanoparticles with different incorporated drug concentration

Docetaxel loaded-P(3HB-co-4HB) nanoparticles were produced using co-polymers characterized by different 4HB monomer contents, i.e. 16 mol% (PHB16), 30 mol% (PHB30) and 70 mol% (PHB70). The incorporation of docetaxel drug into P(3HB-co-4HB) nanoparticles did not affect the size of the obtained nanoparticles when compared with blank P(3HB-co-4HB) nanoparticles. Moreover, no significant particle size variations was evident for all the three different 4HB monomer compositions of nanoparticles produced as shown in Table 1.

Table 1. Characteristics of blank and DCX-loaded P(3HB-co-4HB) nanoparticles prepared by O/W emulsion solvent evaporation method using co-polymers with different 4HB monomer content (Mean \pm SD, n=3).

Nanoparticles Characteristics					
	Size (nm)	PDI	Zeta Potential (mV)	Drug/Polymer Ratio (% w/w)	DCX Conc. (mg/ml)
PHB16	168.2 \pm 0.9	0.121 \pm 0.002	-15.5 \pm 2.2	-	-
PHB30	174.4 \pm 1.5	0.138 \pm 0.005	-21.0 \pm 0.8	-	-
PHB70	169.3 \pm 1.1	0.112 \pm 0.012	-20.5 \pm 1.2	-	-
DCX- PHB16	206.0 \pm 4.5	0.347 \pm 0.020	-9.7 \pm 1.5	40.00	1.0
DCX- PHB30	192.3 \pm 2.9	0.370 \pm 0.020	-8.1 \pm 0.8	40.00	1.0
DCX- PHB70	183.9 \pm 1.3	0.169 \pm 0.008	-9.3 \pm 0.7	40.00	1.0

Blank and DCX-loaded PHB16, PHB30 and PHB70 nanoparticles showed fairly constant particle size below 175.0 nm, while a slight increase in particle size was observed for the drug-loaded nanoparticles. Interestingly, the encapsulation of the drug in P(3HB-co-4HB) nanoparticles appears to decrease the surface charge of the nanoparticles from around -20 mV to values below -10 mV. On the contrary, a significant increase in PDI values for nanoparticles produced with PHB16 and PHB30 co-polymers, indicating a broadening of particle size distribution, while only a slight increase in polydispersity index was evidenced for PHB70-based nanoparticles loaded with docetaxel.

Figure 2 shows a representative SEM image of P(3HB-co-4HB) nanoparticles prepared by solvent evaporation. The DCX loaded P(3HB-co-4HB) nanoparticles were found to be spherical in shape **even if with an irregular surface**. The size of particles was quite homogeneous with dimensions well below 100 nm, while no drug crystals were observed.




Figure 2. SEM image of DCX-loaded P(3HB-co-4HB) nanoparticles (DCX- PHB70).

3.3 P(3HB-co-4HB) nanoparticles docetaxel loading and encapsulation efficiency

The encapsulation efficiency of nanoparticles depends on several factors, including the physicochemical characteristics of the drug and core-forming polymer, the loading method and parameters (Gaucher et al., 2010).




Figure 3. Docetaxel distribution, expressed as percentage of drug precipitated or in agglomerates (black bars), in solution (white bars) and encapsulated in nanoparticles (grey bars) in relation to the total drug recovered, determined for DCX-PHB16 (a), DCX-PHB30 (b) and DCX-PHB70 (c) nanoparticles.

Molecular weight, hydrophobic properties, 4HB monomer compositions as well as other parameters, such as the nature of the solvent used in preparation method and DCX amount (5 to 40% drug/polymer ratio), were found to significantly impact DCX loading efficiency into P(3HB-co-4HB) nanoparticles.

Figure 3 shows that for all three co-polymers tested encapsulation efficiencies ranged from 32 to over 51%. Drug precipitation was evident only for nanoparticles prepared with 40% drug/polymer using PHB16 and PHB70 co-polymers, while was already evident at 30% drug/polymer ratio for PHB30-based nanoparticles. In the case of DCX-PHB16 and DCX-PHB30 encapsulation efficiencies appears to be more variable with an average 40% value. On the other hand, DCX-PHB70 nanoparticles showed more reproducible encapsulation efficiency values quite close to 50% (Figure 3c). Furthermore, even if agglomerates were for the highest drug/polymer ratio, this did not cause an abrupt decrease in NP encapsulation efficiency as evidenced for the other co-polymers.

3.3 *In vitro* P(3HB-co-4HB) nanoparticles docetaxel release

Drug release was studied for DCX-PHB70 produced at different drug/polymer ratios. In fact, overall, DCX-PHB70 nanoparticles demonstrated the most reliable encapsulation efficiency along with small particle size (~175.0 nm), negative surface charge (around -15 mV) and narrow particle size distribution (PDI <0.15). Drug release profiles are shown in Figure 4.




Figure 4. Docetaxel release profile from docetaxel-loaded PHB70 nanoparticles produced with different drug/polymer ratios: 5 (●), 10 (◆), 20 (□), 30 (■) and 40% (○) (n=3, mean ± SD)

From the release profiles, two different behaviors exhibited by docetaxel-loaded PHB70 nanoparticles can be observed. P(3HB-co-4HB) nanoparticles with high drug/polymer ratio led to a relatively rapid release, while nanoparticles with drug/polymer ratio equal or lower than 20% showed more controlled drug release kinetics. In particular, nanoparticles with a drug/polymer ratio of 30 and 40% released more than 80% of docetaxel after 24 hours and after 48 hours the release was almost complete. In the case of lower drug/polymer ratios a biphasic release could be evidenced with an initial “burst” release of ~20-30% of docetaxel in the initial 8 hours, followed by slower release rates with around 60% of drug released after 7 days.

4. Discussion

Despite the growing interest in PHAs application to the biomedical field, the most of researches have focused on their use as resorbable tissue engineering materials, implants, tablets and microparticulate carriers, with a relatively low number of groups exploring their potential as nanoparticulate drug delivery systems [26]. For this reason, in this paper it is presented a thorough investigation of the crucial parameters that could influence the production of P(3HB-co-4HB)

nanoparticles. To start with, was carried out the screening of different types of tensioactives to be used in the nanoparticles preparation by oil-in-water emulsion/solvent evaporation technique. The tensioactives selected, *i.e.* lecithin, Pluronic F-68 and vitamin E-derivative TPGS, were combined with PVA, which has been widely used in literature as stabilizer not only for the production of polymer nanoparticles but also for PHB-based microparticles [27] and nanoparticles [28]. Lecithin, Pluronic F-68 and TPGS were investigated to determine whether these tensioactives could also produce the desired nanoparticles starting from P(3HB-co-4HB) co-polymers. Lecithin was chosen since it is composed of phospholipids, natural components of cell membranes and regularly consumed as part of a normal diet. They are used extensively in pharmaceutical applications as emulsifying, dispersing, and stabilizing agents and are included in intramuscular and intravenous injectables and other parenteral nutrition formulation [29]. Lecithin is a complex mixture of phosphatides consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and other substances such as triglycerides and fatty acids. It is approved by FDA and included in 2013 Inactive Ingredients Guide for Parenterals (*e.g.*, 0.3-2.3% for intramuscular injection). Pluronic F68 is a poloxamer, *i.e.* a triblock co-polymer based on ethylene and propylene oxides. Poloxamers are used as antifoaming agents, wetting agents, dispersants, thickeners, and emulsifiers. Pluronic F68 is mainly used as nonionic surfactant and relatively nontoxic. Due to their amphiphilic character, poloxamers can stabilize nanoparticles surface and mediate the interaction between the polymer and the drug, thus avoiding the formation of flakes and precipitates [30]. Alpha-tocopherol derivative TPGS is a water-soluble form of vitamin E and a polyoxyethylated surfactant [31]. Because of the potential additional adjuvant effects provided vitamin E antioxidant properties in several diseases, TPGS has been proposed as surfactant in a number of different nanoformulations (micelles, nanoemulsions, solid lipid nanoparticles etc.) for several administration routes, such as oral [32,33], topical [32,34], nasal [35], pulmonary [36] and ocular delivery [37]. The screening results evidenced that the best surfactant for P(3HB-co-4HB) nanoparticles production by emulsification/solvent evaporation method was TPGS in association with PVA since allowed for the production of stable monodisperse nanoparticles with particle size around 170 nm and negative surface charge. Pluronic stabilized nanoparticles showed slightly larger particle size, while lecithin led to more variable results in term of surface charge. These differences could be attributed to the polymeric nature of Pluronic surfactant in one case and to the variability of the soybean derived lecithin mixture in the latter.

When different P(3HB-co-4HB) co-polymers (PHB16, PHB30 and PHB70) were used for nanoparticle production and docetaxel was encapsulated at various drug generally the sizes of all the nanoparticles produced didn't exceed the 200 nm size which indicated that the nanoparticles size was not affected by 4HB monomer content in the co-polymer or by drug loading ratio. The electron microscopy images of docetaxel-loaded P(3HB-co-4HB) nanoparticles evidenced particles with an irregular shape and corrugated surface but quite uniformly distributed and the absence of evident drug crystals. The average size of the nanoparticles observed in SEM images was smaller than that determined using dynamic light scattering. However, this is often observed since the particle size determined by DLS measure the hydrodynamic diameter, *i.e.* take into account also the aqueous layer that surrounds the particles. In the case of SEM the sample is dried and metal coated, this leads to the collapse of the hydration layer reducing significantly the apparent size of the nanoparticles observed [38]. Furthermore, drug loading results suggested that P(3HB-co-4HB) nanoparticles produced with the co-polymer with the highest 4HB monomer content (PHB70) is able to incorporate the anticancer drug docetaxel with better reproducibility. In fact, even if DCX-loaded P(3HB-co-4HB) nanoparticles could be prepared with all three different co-polymers without affecting nanoparticle average particle size, lower polydispersity index values were obtained for nanoparticles produced using PHB70. Concerning nanoparticle surface charge, blank nanoparticles showed negative surface charge, as expected due to the presence of terminal carboxylic groups in the P(3HB-co-4HB) polymer chains. However, when docetaxel was loaded in P(3HB-co-4HB) nanoparticles a decrease in zeta potential value was evident. This result appears due to the presence of drug molecules at the surface of nanoparticles produced, able to mask the negative charge bearing polymer chains, as already evidenced by Musumeci and colleagues in the case of docetaxel-loaded PLA nanoparticles [39].

Moreover, the increased proportion of agglomerates and/or precipitated drug shown by nanoparticles at high drug content could be explained, at least in part, by the reduced electrostatic stabilization of nanoparticles. This may be due to the fact that an excess of DCX in the formulation leads to a higher proportion of DCX molecules at the nanoparticle/liquid instead of encapsulated in the nanoparticle polymer core during the preparation stage. This eventually can induce precipitation of the drug and/or the formation of nanoparticle agglomerates, as shown by the abrupt reduction in the nanoparticle encapsulation efficiencies at high drug/polymer ratios. In any case the encapsulation efficiencies obtained, with values close to 50% for nanoparticle prepared using PBH70 co-polymer, appear very promising if considering that docetaxel encapsulation efficiencies for PLA and PLGA nanoparticle was reported to be well below 25% using just 1% drug/polymer ratio [39].

Docetaxel release appears to be dependent on drug/polymer ratio. Drug release from nanoparticulate systems is governed by several factors, including drug location inside the vector and the ease with which the drug molecules are able to diffuse through the nanoparticle core matrix. In particular, burst effects are typically attributed to the release of drug molecules located near the particle surface, upon exposure to sink conditions. In our case, two release patterns were evidenced with faster release (complete release within 48 hours) evidenced by nanoparticles produced high drug/polymer ratio and a burst followed by a prolonged release (60% released after 7 days) for drug/polymer ratios lower than 30%. Interestingly, the group of Leroux comparing polyester nanoparticles loaded with paclitaxel, reports that 90% of the cargo was immediately released in the case of polyhydroxyalkanoate (PHA) nanoparticles, while obtained a bimodal release for nanoparticles prepared using PLA and PLGA, with a burst release followed by sustained release up to 5 days mainly dependent on polymer composition. In particular, the authors attribute the poor encapsulation and fast release of paclitaxel from PHA nanoparticles to a poor drug-polymer compatibility [40]. In our case however, the release profiles are consistent with an initial rapid release of the fraction of the drug more superficially linked to the nanoparticles followed by a controlled release of the drug encapsulated in the polymer matrix [41]. The prolonged release might be due not only to drug diffusion but also to the erosion and degradation of the polymer matrix since DCX had very poor solubility in water [42]. These results clearly evidence that, in terms of drug delivery potential application, PHAs and in particular the naturally derived P(3HB-co-4HB) co-polymer show similar, if not superior, features that widely used biomedical polymers such as PLA and PLGA.

5. Conclusions

The results of the present research have demonstrated that it was possible to prepare nanoparticles using the biodegradable polyester P(3HB-co-4HB) obtained in-house from *Cupriavidus* sp. USMAA1020 using an emulsion/solvent evaporation method. Furthermore, P(3HB-co-4HB) nanoparticles were loaded with the anticancer docetaxel, selected as a model drug. Docetaxel, an anticancer drug with poor aqueous solubility, was successfully encapsulated into nanoparticles without affecting the nanosystem physicochemical properties. The study showed that the release profile was influenced by the drug/polymer ratio. The nanoparticles produced showed average particle size of 140 – 180 nm, PDI value of 0.09 and the particles had smooth surface, spherical in shape and no free drug crystals attached to the particles. Results showed that P(3HB-co-70%4HB) polymer can load docetaxel inside the nanoparticles with no aggregation up to a drug/polymer ratio of 30% with encapsulation efficiency ~ 50%. Furthermore, the release kinetics study also showed that low drug/polymer ratios could lead to prolong release typical of other polyester carriers such as PLGA. High drug loading however led to more rapid release rate with almost the entire encapsulated drug released within 48 hours. These properties showed that P(3HB-co-70%4HB) nanoparticles can be a prospective drug carrier candidate for a controlled release application.

Author Contributions: All authors have read and agree to the published version of the manuscript. Conceptualization, F.S., M.I.A.M. and H.A.W.; methodology, A.A.A.; validation, P.C.; investigation, F.A.F. and F.S.; resources, P.C. and H.A.W.; writing—original draft preparation, F.A.F.; writing—review and editing, F.S., H.A.W.; supervision, P.C., H.A.W. and M.I.A.M.; funding acquisition, P.C. and H.A.W.

Acknowledgments: This research was financially supported by Malaysia Ministry of Science, Technology and Innovation (MOSTI) in collaboration with University of Science Malaysia and University of Parma, Italy.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. George, A.; Shah, P.A.; Shrivastav, P.S. Natural biodegradable polymers based nano-formulations for drug delivery: A review. *Int J Pharm* **2019**, *561*, 244–264, doi:10.1016/j.ijpharm.2019.03.011.
2. Zhao, K.; Li, D.; Shi, C.; Ma, X.; Rong, G.; Kang, H.; Wang, X.; Sun, B. Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug. *Curr Drug Deliv* **2016**, *13*, 494–499, doi:10.2174/156720181304160521004609.
3. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R. Biodegradable polymeric nanoparticles as drug delivery devices. *J Control Rel* **2001**, *70*, 1–20, doi:10.1016/s0168-3659(00)00339-4.
4. Haan, B.J. de; Rossi, A.; Faas, M.M.; Smelt, M.J.; Sonvico, F.; Colombo, P.; Vos, P. de Structural surface changes and inflammatory responses against alginate-based microcapsules after exposure to human peritoneal fluid. *Journal of Biomedical Materials Research Part A* **2011**, *98*, 394–403, doi:10.1002/jbm.a.33123.
5. Martin, D.P.; Williams, S.F. Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable biomaterial. *Biochem Eng J* **2003**, *16*, 97–105, doi:10.1016/s1369-703x(03)00040-8.
6. Barouti, G.; Jaffredo, C.G.; Guillaume, S.M. Advances in drug delivery systems based on synthetic poly(hydroxybutyrate) (co)polymers. *Prog Polym Sci* **2017**, *73*, 1–31, doi:10.1016/j.progpolymsci.2017.05.002.
7. Sudesh, K.; Abe, H.; Doi, Y. Synthesis, structure and properties of polyhydroxyalkanoates: biological polyesters. *Progress in Polymer Science* **2000**, *25*, 1503–1555.
8. Chee, J.-W.; Amirul, A.A.; Muhammad, T.S.T.; Majid, M.I.A.; Mansor, S.M. The influence of copolymer ratio and drug loading level on the biocompatibility of P(3HB-co-4HB) synthesized by *Cupriavidus* sp. (USMAA2-4). *Biochem Eng J* **2008**, *38*, 314–318, doi:10.1016/j.bej.2007.07.018.
9. Valentin, H.E.; Dennis, D. Production of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) in recombinant *Escherichia coli* grown on glucose. *J Biotechnol* **1997**, *58*, 33–38, doi:10.1016/s0168-1656(97)00127-2.
10. Mukai, K.; Yamada, K.; Doi, Y. Efficient hydrolysis of polyhydroxyalkanoates by *Pseudomonas stutzeri* YM1414 isolated from lake water. *Polymer Degradation and Stability* **1994**, *43*, 319–327, doi:10.1016/0141-3910(94)90002-7.
11. Saito, Y.; Nakamura, S.; Hiramitsu, M.; Doi, Y. Microbial Synthesis and Properties of Poly(3-hydroxybutyrate-co-4-hydroxybutyrate). *Pol Int* **1994**, *39*, 169–174.
12. Ying, T.H.; Ishii, D.; Mahara, A.; Murakami, S.; Yamaoka, T.; Sudesh, K.; Samian, R.; Fujita, M.; Maeda, M.; Iwata, T. Scaffolds from electrospun polyhydroxyalkanoate copolymers: Fabrication, characterization, bioabsorption and tissue response. *Biomaterials* **2008**, *29*, 1307–1317, doi:10.1016/j.biomaterials.2007.11.031.
13. Xu, X.-Y.; Li, X.-T.; Peng, S.-W.; Xiao, J.-F.; Liu, C.; Fang, G.; Chen, K.C.; Chen, G.-Q. The behaviour of neural stem cells on polyhydroxyalkanoate nanofiber scaffolds. *Biomaterials* **2010**, *31*, 3967–3975, doi:10.1016/j.biomaterials.2010.01.132.
14. Rao, U.; Sridhar, R.; Sehgal, P.K. Biosynthesis and biocompatibility of poly(3-hydroxybutyrate-co-4-hydroxybutyrate) produced by *Cupriavidus necator* from spent palm oil. *Biochem Eng J* **2010**, *49*, 13–20, doi:10.1016/j.bej.2009.11.005.

15. Shrivastav, A.; Kim, H.-Y.; Kim, Y.-R. Advances in the Applications of Polyhydroxyalkanoate Nanoparticles for Novel Drug Delivery System. *Biomed Res Int* **2013**, *2013*, 1–12, doi:10.1155/2013/581684.
16. Nigmatullin, R.; Thomas, P.; Lukasiewicz, B.; Puthussery, H.; Roy, I. Polyhydroxyalkanoates, a family of natural polymers, and their applications in drug delivery. *J Chem Technology Biotechnology* **2015**, *90*, 1209–1221, doi:10.1002/jctb.4685.
17. Pignatello, R.; Musumeci, T.; Impallomeni, G.; Carnemolla, G.M.; Puglisi, G.; Ballistreri, A. Poly(3-hydroxybutyrate-co- ϵ -caprolactone) copolymers and poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co- ϵ -caprolactone) terpolymers as novel materials for colloidal drug delivery systems. *Eur J Pharm Sci* **2009**, *37*, 451–462, doi:10.1016/j.ejps.2009.03.017.
18. O'Connor, S.; Szwej, E.; Nikodinovic-Runic, J.; O'Connor, A.; Byrne, A.T.; Devocelle, M.; O'Donovan, N.; Gallagher, W.M.; Babu, R.; Kenny, S.T.; et al. The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate. *Biomaterials* **2013**, *34*, 2710–2718, doi:10.1016/j.biomaterials.2012.12.032.
19. Ali, I.; Jamil, N. Polyhydroxyalkanoates: Current applications in the medical field. *Front Biol* **2016**, *11*, 19–27, doi:10.1007/s11515-016-1389-z.
20. Vigneswari, S.; Vijaya, S.; Majid, M.; Sudesh, K.; Sipaut, C.; Azizan, M.; Amirul, A. Enhanced production of poly (3-hydroxybutyrate-co-4-hydroxybutyrate) copolymer with manipulated variables and its properties. *Journal of Industrial Microbiology and Biotechnology* **2009**, *36*, 547–556.
21. Montero, A.; Fossella, F.; Hortobagyi, G.; Valero, V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. *Lancet Oncol* **2005**, *6*, 229–239, doi:10.1016/s1470-2045(05)70094-2.
22. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. *Nature Reviews Cancer* **2004**, *4*, 253–265, doi:10.1038/nrc1317.
23. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. *Adv Drug Deliver Rev* **2002**, *54*, 631–651.
24. Poletto, F.S.; Jäger, E.; Ré, M.I.; Guterres, S.S.; Pohlmann, A.R. Rate-modulating PHBHV/PCL microparticles containing weak acid model drugs. *Int J Pharmaceut* **2007**, *345*, 70–80, doi:10.1016/j.ijpharm.2007.05.040.
25. Agüeros, M.; Ruiz-Gatón, L.; Vauthier, C.; Bouchemal, K.; Espuelas, S.; Ponchel, G.; Irache, J.M. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. *Eur J Pharm Sci* **2009**, *38*, 405–413, doi:10.1016/j.ejps.2009.09.010.
26. Williams, S.F.; Martin, D.P. Applications of Polyhydroxyalkanoates (PHA) in Medicine and Pharmacy. In *Biopolymers Online*; Steinbüchel, A., Ed.; Wiley-VCH: Weinheim, Germany, 2005; pp. 1–38 ISBN 9783527302901.
27. Maia, J.L.; Santana, M.H.A.; Ré, M.I. The effect of some processing conditions on the characteristics of biodegradable microspheres obtained by an emulsion solvent evaporation process. *Braz J Chem Eng* **2004**, *21*, 1–12, doi:10.1590/s0104-66322004000100002.
28. Nachiyar, C.V.; Devi, A.B.; Namasivayam, S.; Raja, K.; Rabel, A.M. Levofloxacin Loaded Polyhydroxybutyrate Nanodrug Conjugate for In-Vitro Controlled Drug Release. *Res J Pharm Biol Chem Sci* **2015**, *6*, 116–119.
29. Lixin, W.; Haibing, H.; Xing, T.; Ruiying, S.; Dawei, C. A less irritant norcantharidin lipid microspheres: Formulation and drug distribution. *Int J Pharmaceut* **2006**, *323*, 161–167, doi:10.1016/j.ijpharm.2006.05.060.
30. Errico, C.; Bartoli, C.; Chiellini, F.; Chiellini, E. Poly(hydroxyalkanoates)-Based Polymeric Nanoparticles for Drug Delivery. *J Biomed Biotechnol* **2009**, *2009*, 571702, doi:10.1155/2009/571702.
31. Jiao, J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. *Advanced drug delivery reviews* **2008**, *60*, 1663–1673, doi:10.1016/j.addr.2008.09.002.

32. Romana, B.; Hassan, Md.M.; Sonvico, F.; Pereira, G.G.; Mason, A.F.; Thordarson, P.; Bremmell, K.E.; Barnes, T.J.; Prestidge, C.A. A Liposome-Micelle-Hybrid (LMH) Oral Delivery System for Poorly Water-Soluble Drugs: Enhancing Solubilisation and Intestinal Transport. *Eur J Pharm Biopharm* **2020**, *154*, 338–347, doi:10.1016/j.ejpb.2020.07.022.
33. Pereira, G.G.; Rawling, T.; Pozzoli, M.; Pazderka, C.; Chen, Y.; Dunstan, C.R.; Murray, M.; Sonvico, F. Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω -3 Fatty Acid Derivatives. *Nanomaterials-basel* **2018**, *8*, 825, doi:10.3390/nano8100825.
34. Telò, I.; Favero, E.D.; Cantù, L.; Frattini, N.; Pescina, S.; Padula, C.; Santi, P.; Sonvico, F.; Nicoli, S. Gel-like TPGS-Based Microemulsions for Imiquimod Dermal Delivery: Role of Mesostructure on the Uptake and Distribution into the Skin. *Mol Pharmaceut* **2017**, *14*, 3281–3289, doi:10.1021/acs.molpharmaceut.7b00348.
35. Cola, E.D.; Cantu', L.; Brocca, P.; Rondelli, V.; Fadda, G.C.; Canelli, E.; Martelli, P.; Clementino, A.; Sonvico, F.; Bettini, R.; et al. Novel O/W nanoemulsions for nasal administration: structural hints in the selection of performing vehicles with enhanced mucopenetration. *Colloids Surfaces B Biointerfaces* **2019**, *183*, 110439, doi:10.1016/j.colsurfb.2019.110439.
36. Rossi, I.; Sonvico, F.; McConville, J.T.; Rossi, F.; Fröhlich, E.; Zellnitz, S.; Rossi, A.; Favero, E.D.; Bettini, R.; Buttini, F. Nebulized coenzyme Q10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy. *European Journal of Pharmaceutical Sciences* **2018**, *113*, 159–170, doi:10.1016/j.ejps.2017.10.024.
37. Grimaudo, M.A.; Pescina, S.; Padula, C.; Santi, P.; Concheiro, A.; Alvarez-Lorenzo, C.; Nicoli, S. Poloxamer 407/TPGS Mixed Micelles as Promising Carriers for Cyclosporine Ocular Delivery. *Mol Pharmaceut* **2018**, *15*, 571–584, doi:10.1021/acs.molpharmaceut.7b00939.
38. Bootz, A.; Vogel, V.; Schubert, D.; Kreuter, J. Comparison of scanning electron microscopy, dynamic light scattering and analytical ultracentrifugation for the sizing of poly(butyl cyanoacrylate) nanoparticles. *European journal of pharmaceuticals and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V* **2004**, *57*, 369–375, doi:10.1016/s0939-6411(03)00193-0.
39. Musumeci, T.; Ventura, C.A.; Giannone, I.; Ruozi, B.; Montenegro, L.; Pignatello, R.; Puglisi, G. PLA/PLGA nanoparticles for sustained release of docetaxel. *Int J Pharmaceut* **2006**, *325*, 172–179, doi:10.1016/j.ijpharm.2006.06.023.
40. Gaucher, G.; Marchessault, R.H.; Leroux, J.-C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. *Journal of controlled release : official journal of the Controlled Release Society* **2010**, *143*, 2–12, doi:10.1016/j.jconrel.2009.11.012.
41. Ling, Y.; Wei, K.; Luo, Y.; Gao, X.; Zhong, S. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy. *Biomaterials* **2011**, *32*, 7139–7150, doi:10.1016/j.biomaterials.2011.05.089.
42. Yanasarn, N.; Sloat, B.R.; Cui, Z. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. *Int J Pharmaceut* **2009**, *379*, 174–180, doi:10.1016/j.ijpharm.2009.06.004.